|
1
|
Muñoz-Martínez S and Forner A: The
tireless search to improve the prognostic assessment of
intrahepatic cholangiocarcinoma: An urgent need. Liver Int.
41:252–254. 2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Saha SK, Zhu AX, Fuchs CS and Brooks GA:
Forty-year trends in cholangiocarcinoma incidence in the U.S.:
Intrahepatic disease on the rise. Oncologist. 21:594–599.
2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Rizvi S, Khan SA, Hallemeier CL, Kelley RK
and Gores GJ: Cholangiocarcinoma-evolving concepts and therapeutic
strategies. Nat Rev Clin Oncol. 15:95–111. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Brunt E, Aishima S, Clavien PA, Fowler K,
Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, et al:
cHCC-CCA: Consensus terminology for primary liver carcinomas with
both hepatocytic and cholangiocytic differentation. Hepatology.
68:113–126. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wu L, Tsilimigras DI, Paredes AZ, Mehta R,
Hyer JM, Merath K, Sahara K, Bagante F, Beal EW, Shen F and Pawlik
TM: Trends in the incidence, treatment and outcomes of patients
with intrahepatic cholangiocarcinoma in the USA: Facility type is
associated with margin status, use of lymphadenectomy and overall
survival. World J Surg. 43:1777–1787. 2019.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Van Dyke AL, Shiels MS, Jones GS, Pfeiffer
RM, Petrick JL, Beebe-Dimmer JL and Koshiol J: Biliary tract cancer
incidence and trends in the United States by demographic group,
1999-2013. Cancer. 125:1489–1498. 2019.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Banales JM, Marin JJG, Lamarca A,
Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen
JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in
mechanisms and management. Nat Rev Gastroenterol Hepatol.
17:557–588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Rahnemai-Azar AA, Weisbrod A, Dillhoff M,
Schmidt C and Pawlik TM: Intrahepatic cholangiocarcinoma: Molecular
markers for diagnosis and prognosis. Surg Oncol. 26:125–137.
2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Massarweh NN and El-Serag HB: Epidemiology
of hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Cancer Control. 24(1073274817729245)2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Fujita T: Liver transplantation for
intrahepatic cholangiocarcinoma. Lancet. 384(1182)2014.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al: Guidelines for the diagnosis and
treatment of cholangiocarcinoma: An update. Gut. 61:1657–1669.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Lamarca A, Ross P, Wasan HS, Hubner RA,
McNamara MG, Lopes A, Manoharan P, Palmer D, Bridgewater J and
Valle JW: Advanced intrahepatic cholangiocarcinoma: Post hoc
analysis of the ABC-01, -02, and -03 clinical trials. J Natl Cancer
Inst. 112:200–210. 2020.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Ryerson AB, Eheman CR, Altekruse SF, Ward
JW, Jemal A, Sherman RL, Henley SJ, Holtzman D, Lake A, Noone AM,
et al: Annual report to the nation on the status of cancer,
1975-2012, featuring the increasing incidence of liver cancer.
Cancer. 122:1312–1337. 2016.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Hamidi H and Ivaska J: Every step of the
way: Integrins in cancer progression and metastasis. Nat Rev
Cancer. 18:533–548. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Humphries JD, Byron A and Humphries MJ:
Integrin ligands at a glance. J Cell Sci. 119:3901–3903.
2006.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Arruda Macêdo JK, Fox JW and de Souza
Castro M: Disintegrins from snake venoms and their applications in
cancer research and therapy. Curr Protein Pept Sci. 16:532–548.
2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Hussein HA, Walker LR, Abdel-Raouf UM,
Desouky SA, Montasser AK and Akula SM: Beyond RGD: Virus
interactions with integrins. Arch Virol. 160:2669–2681.
2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao ZS, Wang YY, Chu YQ, Ye ZY and Tao
HQ: SPARC is associated with gastric cancer progression and poor
survival of patients. Clin Cancer Res. 16:260–268. 2010.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Petricevic B, Vrbanec D, Jakic-Razumovic
J, Brcic I, Rabic D, Badovinac T, Ozimec E and Bali V: Expression
of Toll-like receptor 4 and beta 1 integrin in breast cancer. Med
Oncol. 29:486–494. 2012.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhou G, Chiu D, Qin D, Niu L, Cai J, He L,
Tan D and Xu K: Expression of CD44v6 and integrin-β1 for the
prognosis evaluation of pancreatic cancer patients after
cryosurgery. Diagn Pathol. 8(146)2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Liu QZ, Gao XH, Chang WJ, Gong HF, Fu CG,
Zhang W and Cao GW: Expression of ITGB1 predicts prognosis in
colorectal cancer: A large prospective study based on tissue
microarray. Int J Clin Exp Pathol. 8:12802–12810. 2015.PubMed/NCBI
|
|
22
|
Takada Y, Ye X and Simon S: The integrins.
Genome Biol. 8(215)2007.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Shi W, He J, Huang Y, Zeng Z, Feng Z, Xu H
and Nie Y: Integrin β5 enhances the malignancy of human colorectal
cancer by increasing the TGF-β signaling. Anticancer Drugs.
32:717–726. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lin Z, He R, Luo H, Lu C, Ning Z, Wu Y,
Han C, Tan G and Wang Z: Integrin-β5, a miR-185-targeted gene,
promotes hepatocellular carcinoma tumorigenesis by regulating
β-catenin stability. J Exp Clin Cancer Res. 37(17)2018.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wortzel I, Dror S, Kenific CM and Lyden D:
Exosome-mediated metastasis: Communication from a distance. Dev
Cell. 49:347–360. 2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Shang L, Ye X, Zhu G, Su H, Su Z, Chen B,
Xiao K, Li L, Peng M and Peng T: Prognostic value of integrin
variants and expression in post-operative patients with HBV-related
hepatocellular carcinoma. Oncotarget. 8:76816–76831.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Andersen JB, Spee B, Blechacz BR, Avital
I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts
LR, et al: Genomic and genetic characterization of
cholangiocarcinoma identifies therapeutic targets for tyrosine
kinase inhibitors. Gastroenterology. 142:1021–1031.e15.
2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ahn KS, O'Brien D, Kang YN, Mounajjed T,
Kim YH, Kim TS, Kocher JA, Allotey LK, Borad MJ, Roberts LR and
Kang KJ: Prognostic subclass of intrahepatic cholangiocarcinoma by
integrative molecular-clinical analysis and potential targeted
approach. Hepatol Int. 13:490–500. 2019.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Davis S and Meltzer PS: GEOquery: A bridge
between the gene expression omnibus (GEO) and Bioconductor.
Bioinformatics. 23:1846–1847. 2007.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Colaprico A, Silva TC, Olsen C, Garofano
L, Cava C, Garolini D, Sabedot TS, Malta TM, Pagnotta SM,
Castiglioni I, et al: TCGAbiolinks: An R/Bioconductor package for
integrative analysis of TCGA data. Nucleic Acids Res.
44(e71)2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Chen C, Chen H, Zhang Y, Thomas HR, Frank
MH, He Y and Xia R: TBtools: An integrative toolkit developed for
interactive analyses of big biological data. Mol Plant.
13:1194–1202. 2020.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2020.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Chun YS, Pawlik TM and Vauthey JN: 8th
Edition of the AJCC cancer staging manual: Pancreas and
hepatobiliary cancers. Ann Surg Oncol. 25:845–847. 2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
The Gene Ontology Consortium. The gene
ontology resource: 20 Years and still GOing strong. Nucleic Acids
Res. 47 (D1):D330–D338. 2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Kanehisa M and Goto S: KEGG: Kyoto
encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30.
2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou Y, Zhou B, Pache L, Chang M,
Khodabakhshi AH, Tanaseichuk O, Benner C and Chanda SK: Metascape
provides a biologist-oriented resource for the analysis of
systems-level datasets. Nat Commun. 10(1523)2019.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45
(W1):W98–W102. 2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Gao C, Li J, Zeng F, Wang L, Chen K, Chen
D, Hong J and Qu C: MCM6 promotes intrahepatic cholangiocarcinoma
progression by upregulating E2F1 and enhancing
epithelial-mesenchymal transition. Carcinogenesis. 44:279–290.
2023.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang JN, Ding DY, Yang SY, Tao QF, Yang Y
and Zhou WP: The role of tripartite motif containing 59 (TRIM59) in
the proliferation and prognosis of intrahepatic cholangiocarcinoma.
Pathol Res Pract. 236(153989)2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Nakamura H, Arai Y, Totoki Y, Shirota T,
Elzawahry A, Kato M, Hama N, Hosoda F, Urushidate T, Ohashi S, et
al: Genomic spectra of biliary tract cancer. Nat Genet.
47:1003–1010. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Sia D, Hoshida Y, Villanueva A, Roayaie S,
Ferrer J, Tabak B, Peix J, Sole M, Tovar V, Alsinet C, et al:
Integrative molecular analysis of intrahepatic cholangiocarcinoma
reveals 2 classes that have different outcomes. Gastroenterology.
144:829–840. 2013.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Liu J, Ren G, Li K, Liu Z, Wang Y, Chen T,
Mu W, Yang X, Li X, Shi A, et al: The Smad4-MYO18A-PP1A complex
regulates β-catenin phosphorylation and pemigatinib resistance by
inhibiting PAK1 in cholangiocarcinoma. Cell Death Differ.
29:818–831. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Hozaka Y, Seki N, Tanaka T, Asai S, Moriya
S, Idichi T, Wada M, Tanoue K, Kawasaki Y, Mataki Y, et al:
Molecular pathogenesis and regulation of the miR-29-3p-family:
Involvement of ITGA6 and ITGB1 in intra-hepatic cholangiocarcinoma.
Cancers (Basel). 13(2804)2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Ricono JM, Huang M, Barnes LA, Lau SK,
Weis SM, Schlaepfer DD, Hanks SK and Cheresh DA: Specific
cross-talk between epidermal growth factor receptor and integrin
alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer
Res. 69:1383–1391. 2009.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Bianchi-Smiraglia A, Paesante S and Bakin
AV: Integrin β5 contributes to the tumorigenic potential of breast
cancer cells through the Src-FAK and MEK-ERK signaling pathways.
Oncogene. 32:3049–3058. 2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Hung WY, Huang KH, Wu CW, Chi CW, Kao HL,
Li AF, Yin PH and Lee HC: Mitochondrial dysfunction promotes cell
migration via reactive oxygen species-enhanced β5-integrin
expression in human gastric cancer SC-M1 cells. Biochim Biophys
Acta. 1820:1102–1110. 2012.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Tancioni I, Uryu S, Sulzmaier FJ, Shah NR,
Lawson C, Miller NL, Jean C, Chen XL, Ward KK and Schlaepfer DD:
FAK inhibition disrupts a β5 integrin signaling axis controlling
anchorage-independent ovarian carcinoma growth. Mol Cancer Ther.
13:2050–2061. 2014.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhang LY, Guo Q, Guan GF, Cheng W, Cheng P
and Wu AH: Integrin beta 5 is a prognostic biomarker and potential
therapeutic target in glioblastoma. Front Oncol.
9(904)2019.PubMed/NCBI View Article : Google Scholar
|
|
52
|
An XZ, Zhao ZG, Luo YX, Zhang R, Tang XQ,
Hao D, Zhao X, Lv X and Liu D: Netrin-1 suppresses the MEK/ERK
pathway and ITGB4 in pancreatic cancer. Oncotarget. 7:24719–24733.
2016.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Yang GY, Guo S, Dong CY, Wang XQ, Hu BY,
Liu YF, Chen YW, Niu J and Dong JH: Integrin αvβ6 sustains and
promotes tumor invasive growth in colon cancer progression. World J
Gastroenterol. 21:7457–7467. 2015.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Reader CS, Vallath S, Steele CW, Haider S,
Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, et
al: The integrin αvβ6 drives pancreatic cancer through diverse
mechanisms and represents an effective target for therapy. J
Pathol. 249:332–342. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hurtado de Mendoza T, Mose ES, Botta GP,
Braun GB, Kotamraju VR, French RP, Suzuki K, Miyamura N, Teesalu T,
Ruoslahti E, et al: Tumor-penetrating therapy for β5 integrin-rich
pancreas cancer. Nat Commun. 12(1541)2021.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Hoshino A, Costa-Silva B, Shen TL,
Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di
Giannatale A, Ceder S, et al: Tumour exosome integrins determine
organotropic metastasis. Nature. 527:329–335. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Li H, Long J, Xie F, Kang K, Shi Y, Xu W,
Wu X, Lin J, Xu H, Du S, et al: Transcriptomic analysis and
identification of prognostic biomarkers in cholangiocarcinoma.
Oncol Rep. 42:1833–1842. 2019.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Wu D, Sun J, Wang H and Ma C: LncRNA
SOCS2-AS1 promotes the progression of glioma via regulating ITGB1
expression. Neurosci Lett. 765(136248)2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Que ZJ, Yang Y, Liu HT, Shang-Guan WJ, Yu
P, Zhu LH, Li HG, Liu HM and Tian JH: Jinfukang regulates
integrin/Src pathway and anoikis mediating circulating lung cancer
cells migration. J Ethnopharmacol. 267(113473)2021.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Bergamaschi A, Tagliabue E, Sørlie T,
Naume B, Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R,
Auvinen P, et al: Extracellular matrix signature identifies breast
cancer subgroups with different clinical outcome. J Pathol.
214:357–367. 2008.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Yang J, Hou Y, Zhou M, Wen S, Zhou J, Xu
L, Tang X, Du YE, Hu P and Liu M: Twist induces
epithelial-mesenchymal transition and cell motility in breast
cancer via ITGB1-FAK/ILK signaling axis and its associated
downstream network. Int J Biochem Cell Biol. 71:62–71.
2016.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Eke I and Cordes N: Focal adhesion
signaling and therapy resistance in cancer. Semin Cancer Biol.
31:65–75. 2015.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Murphy JM, Rodriguez YAR, Jeong K, Ahn EE
and Lim SS: Targeting focal adhesion kinase in cancer cells and the
tumor microenvironment. Exp Mol Med. 52:877–886. 2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Liu D, Liu S, Fang Y, Liu L and Hu K:
Comprehensive analysis of the expression and prognosis for ITGBs:
Identification of ITGB5 as a biomarker of poor prognosis and
correlated with immune infiltrates in gastric cancer. Front Cell
Dev Biol. 9(816230)2022.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Yang X, Chen L, Mao Y, Hu Z and He M:
Progressive and prognostic performance of an extracellular
matrix-receptor interaction signature in gastric cancer. Dis
Markers. 2020(8816070)2020.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Shimizu S, Okumura T, Oshiro Y, Fukumitsu
N, Fukuda K, Ishige K, Hasegawa N, Numajiri H, Murofushi K, Ohnishi
K, et al: Clinical outcomes of previously untreated patients with
unresectable intrahepatic cholangiocarcinoma following proton beam
therapy. Radiat Oncol. 14(241)2019.PubMed/NCBI View Article : Google Scholar
|
